US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Zealand Pharma A/S

69.32

+6.9611.17%

Volume:249.00

Turnover:17.24K

Market Cap:4.92B

PE:-38.36

High:69.32

Open:69.32

Low:69.32

Close:62.36

Loading ...

Overview Company News Filings

Zealand Pharma appoints Johnson as Chief Development Officer

Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results

Zealand Pharma AS (ZLDPF) Stock Jumps 8.0%: Will It Continue to Soar?

Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery

Repligen (RGEN) Moves 3.7% Higher: Will This Strength Last?

Total number of shares and voting rights in Zealand Pharma as of March 31, 2025

Resolutions from Zealand Pharma's Annual General Meeting 2025

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Zealand Pharma completes enrollment in ZUPREME-1 trial

Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity

NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand

Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update

Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity

Zealand Pharma removed from European Conviction List at Goldman Sachs

Zealand Pharma initiated with a Market Perform at William Blair

Zealand Pharma price target lowered to DKK 1,050 from DKK 1,080 at Berenberg

BTIG Sticks to Its Buy Rating for Zealand Pharma (ZLDPF)

Zealand Pharma AS (ZLDPF) Q4 2024 Earnings Call Highlights: Strong Cash Position and Obesity ...

Zealand Pharma convenes its Annual General Meeting 2025

Zealand Pharma Announces Financial Results for the Full Year 2024

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ZLDPF/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ZLDPF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZLDPF\",,,,,undefined,":{"symbol":"ZLDPF","market":"US","secType":"STK","nameCN":"Zealand Pharma A/S","latestPrice":69.32,"timestamp":1748373985921,"preClose":62.3556,"halted":0,"volume":249,"delay":15,"floatShares":60575983,"shares":70935412,"eps":-1.807241,"marketStatus":"Post-Mkt","change":6.9644,"latestTime":"05-27 15:26:25 EDT Delay","open":69.32,"high":69.32,"low":69.32,"amount":17244.73,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-1.807241,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1748390400000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"PINK LIMITED","adjPreClose":62.3556,"volumeRatio":1.008098},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZLDPF\",,,,,undefined,":{"symbol":"ZLDPF","floatShares":60575983,"roa":"-13.97%","roe":"-21.27%","lyrEps":-1.844231,"volumeRatio":1.008098,"shares":70935412,"dividePrice":0,"high":69.32,"amplitude":0,"preClose":62.3556,"low":69.32,"week52Low":57.97,"pbRate":"4.02","psRate":"599.90","week52High":141.742,"institutionHeld":0,"latestPrice":69.32,"eps":-1.807241,"divideRate":0,"volume":249,"delay":15,"ttmEps":-1.807241,"open":69.32,"prevYearClose":102.36,"prevWeekClose":62.3556,"prevMonthClose":72.28,"prevQuarterClose":75.6,"fiveDayClose":62.196,"twentyDayClose":65.16,"sixtyDayClose":97.78},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ZLDPF\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2536682068","title":"Zealand Pharma appoints Johnson as Chief Development Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2536682068","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536682068?lang=en_us&edition=fundamental","pubTime":"2025-05-19 21:10","pubTimestamp":1747660245,"startTime":"0","endTime":"0","summary":"Zealand Pharma (ZLDPF) announces the appointment of Steven Johnson as Chief Development Officer. Steven will join the executive team to lead regula...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zealand-pharma-appoints-johnson-as-chief-development-officer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zealand-pharma-appoints-johnson-as-chief-development-officer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZLDPF","BK4139"],"gpt_icon":0},{"id":"2532004577","title":"Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2532004577","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532004577?lang=en_us&edition=fundamental","pubTime":"2025-05-01 23:05","pubTimestamp":1746111900,"startTime":"0","endTime":"0","summary":"Copenhagen, Denmark,May 1, 2025–Zealand Pharma A/S  , a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on May 8, 2025, at 2:00 pm CET  following the announcement of financial results for the first quarter / first three months of 2025.Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; Chief Medical Officer, David Kendall; and Chief Commercial Officer, Eric Cox. The presentation will be followed by a Q&A session.Zealand Pharma A/S  is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial pa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zealand-pharma-conference-call-may-150500602.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","ET","BK4581","BK4139","BK4590","BK4561","ZLDPF","BK4588","BK4144"],"gpt_icon":0},{"id":"2532887022","title":"Zealand Pharma AS (ZLDPF) Stock Jumps 8.0%: Will It Continue to Soar?","url":"https://stock-news.laohu8.com/highlight/detail?id=2532887022","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532887022?lang=en_us&edition=fundamental","pubTime":"2025-05-01 16:23","pubTimestamp":1746087780,"startTime":"0","endTime":"0","summary":"Zealand Pharma A/S  shares ended the last trading session 8% higher at $72.28. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 0.3% loss over the past four weeks.Last month, the company announced that it has enrolled the first participant in the phase IIb ZUPREME-2 study. This study evaluates the efficacy and safety of petrelintide versus placebo in people with obesity and type 2 diabetes. Enrollment in the ZUPREME-2 study is expected to be completed in the second half of 2025. The growing optimism related to the development of petrelintide might have driven the recent share price rally.Zealand Pharma AS belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Akoya Biosciences , closed the last trading session 5.5% lower at $1.20. Over the past month, AKYA has returned -5.9%.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zealand-pharma-zldpf-stock-jumps-082300223.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4121","BK4139","ZLDPF","BK4539","AKYA"],"gpt_icon":0},{"id":"2529446683","title":"Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery","url":"https://stock-news.laohu8.com/highlight/detail?id=2529446683","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529446683?lang=en_us&edition=fundamental","pubTime":"2025-04-23 21:00","pubTimestamp":1745413200,"startTime":"0","endTime":"0","summary":"Utpal joins Zealand Pharma at a pivotal moment as it aims to become a leader in the management of obesity and related complications. He will lead the discovery and clinical translation of peptide medicines, investing in new technologies including data and computational science. Utpal to expand the global scientific team to drive Zealand Pharma’s next wave of highly differentiated, innovative therapies, building on the Company’s strong drug development heritage. Copenhagen, Denmark, 23 April 2025 –Zealand Pharma A/S  , a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the appointment of Utpal Singh as Chief Scientific Officer. Utpal will join the executive team to lead discovery research and translational sciences at Zealand Pharma.Zealand Pharma A/S   is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug ca","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zealand-pharma-appoints-utpal-singh-130000184.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ZLDPF"],"gpt_icon":0},{"id":"2525386346","title":"Repligen (RGEN) Moves 3.7% Higher: Will This Strength Last?","url":"https://stock-news.laohu8.com/highlight/detail?id=2525386346","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525386346?lang=en_us&edition=fundamental","pubTime":"2025-04-08 16:11","pubTimestamp":1744099860,"startTime":"0","endTime":"0","summary":"Repligen RGEN shares soared 3.7% in the last trading session to close at $116.11. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 28.1% loss over the past four weeks.Positive investor sentiment for Repligen's various business segments might have driven the recent share price rally. The company recently purchased 908 Devices’ desktop portfolio of four devices for bioprocessing process analytical technology applications to improve its manufacturing efficiencies.This drug developer is expected to post quarterly earnings of $0.35 per share in its upcoming report, which represents a year-over-year change of +25%. Revenues are expected to be $164.48 million, up 8.7% from the year-ago quarter.Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock pr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/repligen-rgen-moves-3-7-081100841.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4121","RGEN","BK4139","LU0757428866.USD","ZLDPF","LU1815336091.USD"],"gpt_icon":0},{"id":"2524204970","title":"Total number of shares and voting rights in Zealand Pharma as of March 31, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524204970","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524204970?lang=en_us&edition=fundamental","pubTime":"2025-04-01 05:00","pubTimestamp":1743454800,"startTime":"0","endTime":"0","summary":"Copenhagen, Denmark, March 31, 2025 – Zealand Pharma A/S   , a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar month during which changes to its share capital have occurred.In Company Announcement No. 5 / 2025 dated March 20, 2025, Zealand Pharma announced a share capital increase due to the exercise of employee warrants. Following this announcement, the table below details the total number of shares and voting rights in Zealand Pharma as of March 31, 2025.About Zealand Pharma A/SZealand Pharma A/S   is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/total-number-shares-voting-rights-210000958.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TSS","BK4139","ZLDPF"],"gpt_icon":0},{"id":"2522331325","title":"Resolutions from Zealand Pharma's Annual General Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2522331325","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522331325?lang=en_us&edition=fundamental","pubTime":"2025-03-28 01:20","pubTimestamp":1743096000,"startTime":"0","endTime":"0","summary":"Copenhagen, Denmark, March 27, 2025 - Zealand Pharma A/S   , a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today held its Annual General Meeting of 2025 as a partly electronic and partly physical general meeting .At the Annual General Meeting, all proposals presented to the Annual General Meeting were approved.The Annual General Meeting acknowledged the management's report on Zealand Pharma's activities in the past financial year and Zealand Pharma's audited Annual Report for 2024 was approved. The Annual General Meeting also approved that the financial result for 2024, which was a loss of TDKK 1,078,828, was carried forward to the next financial year.All existing shareholder-elected board members were re-elected to the Board of Directors as recommended by Zealand Pharma's Nomination Committee:. The Nomination Committee will compromise Leonard Kruimer and Martin Nicklasson, with Kirsten Aarup Drejer chairing the Committee.Zealan","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/resolutions-zealand-pharmas-annual-general-172000045.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ZLDPF","BK4139"],"gpt_icon":0},{"id":"2521467649","title":"Zealand Pharma increases its share capital as a result of the exercise of employee warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2521467649","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521467649?lang=en_us&edition=fundamental","pubTime":"2025-03-21 00:00","pubTimestamp":1742486400,"startTime":"0","endTime":"0","summary":"Copenhagen, Denmark, March 20, 2025 – Zealand Pharma A/S   , a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 27,425 divided into 27,425 new shares with a nominal value of DKK 1 each. The capital increase is a consequence of the exercise of warrants granted under two of Zealand Pharma's employee warrant programs.The exercise price was DKK 224.40 per share for 7,917 of new shares and DKK 90.70 per share for 19,508 of new shares. The total proceeds to Zealand Pharma from the capital increase amount to DKK 3,545,950.40.Zealand Pharma A/S   is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development pa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zealand-pharma-increases-share-capital-160000209.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ZLDPF","ZEAL","BK4139"],"gpt_icon":0},{"id":"2520514251","title":"Zealand Pharma completes enrollment in ZUPREME-1 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2520514251","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520514251?lang=en_us&edition=fundamental","pubTime":"2025-03-17 17:30","pubTimestamp":1742203818,"startTime":"0","endTime":"0","summary":"Zealand Pharma (ZLDPF) announced that the last participant has been enrolled and randomized to active treatment or placebo in ZUPREME-1, a global P...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zealand-pharma-completes-enrollment-in-zupreme-1-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zealand-pharma-completes-enrollment-in-zupreme-1-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZLDPF","BK4139"],"gpt_icon":0},{"id":"2520456013","title":"Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2520456013","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520456013?lang=en_us&edition=fundamental","pubTime":"2025-03-17 15:00","pubTimestamp":1742194800,"startTime":"0","endTime":"0","summary":"Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity. Initiated in December 2024, the Phase 2b ZUPREME-1 trial is designed to evaluate five target doses of petrelintide up to 9 mg over 42 weeks of treatment.Zealand Pharma remains on track to initiate the Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes in the first half of 2025.“We are excited to announce the rapid completion of enrollment and randomization in the Phase 2b ZUPREME-1 clinical trial with petrelintide in people with overweight or obesity, just three months after initiation”, said David Kendall, MD, Chief Medical Officer of Zealand Pharma. “This achievement reflects both the strong interest in amylin agonists from the clinical community and highlights the importance of developing new treatment options that can leverage distinct mechanisms of action to better serve those living with overweight a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zealand-pharma-announces-completion-enrollment-070000562.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ZLDPF"],"gpt_icon":0},{"id":"2519863829","title":"NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand","url":"https://stock-news.laohu8.com/highlight/detail?id=2519863829","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519863829?lang=en_us&edition=fundamental","pubTime":"2025-03-14 01:23","pubTimestamp":1741886580,"startTime":"0","endTime":"0","summary":"Novo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 billion with Denmark’s Zealand Pharma to co-develop its lead obesity candidate petrelintide. Roche’s latest deal increases competition in the obesity space.Roche Buys Rights to Obesity Drug From Zealand Pharma. Amylin drugs work similarly to the popular GLP-1 drugs ruling the obesity space. The GLP-1 space is dominated by NVO and Eli Lilly LLY, with their popular obesity injections, Wegovy  and Zepbound , respectively. Like GLP-1 drugs mimica naturally occurring hormone, GLP-1, to regulate blood sugar and promote weight loss, amylin drugs mimic another natural hormone amylin, which is secreted at the same time as insulin in response to food intake. Amylin drugs are being considered the next generation of obesity medicines after the current GLP-1 medicines.NVO’s stock has plunged 44.4% in the past year compared with a decrease of 5.2% for the industry.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nvo-stock-slips-4-roche-172300319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SGXZ51526630.SGD","LU0820561818.USD","LU0058720904.USD","LU1868837136.USD","BK4599","CDMO","03165","LU2360106947.USD","NVO","SG9999018865.SGD","BK4581","LU0061475181.USD","LU1291159041.SGD","LU1720051108.HKD","IE00BJLML261.HKD","BK4007","SG9999014898.SGD","SG9999015945.SGD","LU2602419157.SGD","IE00B4R5TH58.HKD","LU1093756168.USD","LU2106854487.HKD","LU2491050154.USD","LU0385154629.USD","LU0256863902.USD","LU1551013425.SGD","LU2237443549.SGD","LU2264538146.SGD","SG9999001176.USD","VKTX","IE00BK4W5M84.HKD","LU1548497426.USD","LU2089984988.USD","LU1127390331.HKD","LU1069344957.HKD","LU0882574139.USD","LU0417517546.SGD","LU1814569148.SGD","SG9999017495.SGD","LU2112291526.USD","LU2237443465.HKD","LU2023250504.SGD","LU2237443622.USD","LU2324357040.USD","LU2491049909.HKD","LU0466842654.USD","SG9999015986.USD","RHHBY","ZLDPF"],"gpt_icon":1},{"id":"2519863822","title":"Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2519863822","media":"Zacks","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519863822?lang=en_us&edition=fundamental","pubTime":"2025-03-14 01:05","pubTimestamp":1741885500,"startTime":"0","endTime":"0","summary":"This week, Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche RHHBY announced a license and collaboration deal with Denmark’s Zealand Pharma to co-develop its lead obesity candidate petrelintide. Pfizer PFE and partner Arvinas ARVN announced mixed phase III data for breast cancer therapy, vepdegestrant. J&J JNJ and partner Protagonist Therapeutics’ investigational targeted oral peptide, icotrokinra met the primary endpoint of clinical response in ulcerative colitis study.Here's a recap of the week’s most important stories.NVO's Novel Obesity Treatment Disappoints in Phase III Study. Novo Nordisk’sphase III REDEFINE 2 study evaluating its next-gen subcutaneous obesity candidate, CagriSema, met its primary endpoint. CagriSema is a fixed-dose combination of a long-acting amylin analog, cagrilintide  and semaglutide .In the study, 61.9% of patients were given the highest dose of the drug.For the deal, Roche will make an upfro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharma-stock-roundup-rhhby-obesity-170500925.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999003800.SGD","LU1894683264.USD","LU0058720904.USD","LU2112291526.USD","LU2602419157.SGD","LU0053671581.USD","IE00B42XCP33.USD","LU1732799900.SGD","LU2129689605.HKD","SG9999001176.USD","LU0345770993.USD","ARVN","LU0225284248.USD","IE00B4R5TH58.HKD","LU1430594728.SGD","IE00BLSP4239.USD","BK4581","LU1032466523.USD","LU0345769128.USD","LU1093756168.USD","ITT","SG9999011175.SGD","JNJ","LU0795875086.SGD","LU0912757837.SGD","LU1032955483.USD","LU2089984988.USD","IE00B19Z3581.USD","LU0054578231.USD","LU1261432733.SGD","RHHBY","BK4599","LU0466842654.USD","LU1718418525.SGD","LU2430703095.HKD","BK4007","MBC","PFE","LU0345769631.USD","BK4559","ZLDPF","03165","IE00BDGV0183.EUR","LU1244550221.USD","LU2505996509.AUD","LU1066051811.HKD","SG9999002232.USD","IE00BGHQF631.EUR","NVO","LU0234570918.USD"],"gpt_icon":1},{"id":"2518567037","title":"Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2518567037","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518567037?lang=en_us&edition=fundamental","pubTime":"2025-03-12 14:00","pubTimestamp":1741759200,"startTime":"0","endTime":"0","summary":"Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity. The companies will co-develop and co-commercialize petrelintide monotherapy and potential combination products, including petrelintide/CT-388, in the U.S. and Europe. Zealand Pharma will receive upfront cash payments of USD 1.65 billion, including USD 1.4 billion due at closing and USD 250 million in anniversary payments over two years, as well as potential milestone payments, for a total consideration of up to USD 5.3 billion. Profits and losses will be shared on a 50/50 basis for petrelintide and petrelintide/CT-388 in the U.S. and Europe, and Zealand Pharma is eligible to royalties on net sales in the rest of the world. Zealand Pharma will pay Roche USD 350 million for the contribution of CT-388 in the first combination product arising from the collaboration. Collaboration and license agreement aim","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zealand-pharma-roche-enter-collaboration-060000779.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ZLDPF"],"gpt_icon":0},{"id":"2516685687","title":"Zealand Pharma removed from European Conviction List at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2516685687","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516685687?lang=en_us&edition=fundamental","pubTime":"2025-03-03 17:30","pubTimestamp":1740994247,"startTime":"0","endTime":"0","summary":"Goldman Sachs analysts removed Zealand Pharma (ZLDPF) from the firm’s European Conviction List as part of its monthly update. Published first on Th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zealand-pharma-removed-from-european-conviction-list-at-goldman-sachs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zealand-pharma-removed-from-european-conviction-list-at-goldman-sachs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1791807156.HKD","LU1868836914.USD","IE0002270589.USD","BK4516","LU2750360641.GBP","BK4139","BK4585","LU0096364046.USD","IE0004091025.USD","IE00BFXG1179.USD","BK4533","BK4550","BK4504","LU0106831901.USD","LU2237438978.USD","BK4588","LU1668664300.SGD","LU1868836591.USD","LU2237443382.USD","LU2237443895.HKD","LU2471134523.USD","LU1868836757.USD","LU1868837136.USD","LU2237443978.SGD","ZLDPF","IE00B19Z3B42.SGD","IE00BSNM7G36.USD","LU2471134952.CNY","BK4127","IE0034235188.USD","LU0061475181.USD","LU1868837300.USD","LU2471134879.HKD","LU2471134796.USD","LU2237443622.USD","BK4552","LU2237443465.HKD","IE00B19Z3581.USD","IE0004086264.USD","LU2237443549.SGD","LU2750360997.AUD"],"gpt_icon":0},{"id":"2514359878","title":"Zealand Pharma initiated with a Market Perform at William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2514359878","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514359878?lang=en_us&edition=fundamental","pubTime":"2025-02-28 06:20","pubTimestamp":1740694830,"startTime":"0","endTime":"0","summary":"William Blair initiated coverage of Zealand Pharma (ZLDPF) with a Market Perform rating. Published first on TheFly – the ultimate source for real-t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zealand-pharma-initiated-with-a-market-perform-at-william-blair?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zealand-pharma-initiated-with-a-market-perform-at-william-blair?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ZLDPF"],"gpt_icon":0},{"id":"2514033117","title":"Zealand Pharma price target lowered to DKK 1,050 from DKK 1,080 at Berenberg","url":"https://stock-news.laohu8.com/highlight/detail?id=2514033117","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514033117?lang=en_us&edition=fundamental","pubTime":"2025-02-25 03:51","pubTimestamp":1740426678,"startTime":"0","endTime":"0","summary":"Berenberg lowered the firm’s price target on Zealand Pharma (ZLDPF) to DKK 1,050 from DKK 1,080 and keeps a Buy rating on the shares. Published fir...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zealand-pharma-price-target-lowered-to-dkk-1050-from-dkk-1080-at-berenberg?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zealand-pharma-price-target-lowered-to-dkk-1050-from-dkk-1080-at-berenberg?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZLDPF","BK4139"],"gpt_icon":0},{"id":"2513266876","title":"BTIG Sticks to Its Buy Rating for Zealand Pharma (ZLDPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2513266876","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513266876?lang=en_us&edition=fundamental","pubTime":"2025-02-21 19:17","pubTimestamp":1740136637,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Zealand Pharma (ZLDPF – Research Report), with a price target ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/btig-sticks-to-its-buy-rating-for-zealand-pharma-zldpf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/btig-sticks-to-its-buy-rating-for-zealand-pharma-zldpf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZLDPF"],"gpt_icon":0},{"id":"2513723722","title":"Zealand Pharma AS (ZLDPF) Q4 2024 Earnings Call Highlights: Strong Cash Position and Obesity ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2513723722","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513723722?lang=en_us&edition=fundamental","pubTime":"2025-02-21 15:04","pubTimestamp":1740121496,"startTime":"0","endTime":"0","summary":"Revenue: DKK63 million for the full year 2024, primarily from the license and development agreement with Novo Nordisk for Zegalogue.Net Operating Expenses: DKK1.33 billion, within the guidance range of DKK1.25 billion to DKK1.35 billion.R&D Expenses: DKK920 million, representing 69% of operating expenses, driven by clinical advancement of obesity assets.Selling and Marketing Expenses: DKK88 million, mainly for pre-commercial activities for rare disease assets.Net Financial Items: Net gain of DKK189 million, compared to a net loss of DKK137 million in 2023, due to interest income from marketable securities.Cash Position: DKK9 billion as of December 31, 2024, an increase of DKK7.4 billion from the start of the year.2025 Operating Expenses Guidance: Expected to be between DKK2.0 billion and DKK2.5 billion, to support mid-stage obesity pipeline and early-stage research efforts.GuruFocus has detected 6 Warning Signs with ZLDPF.Zealand Pharma AS  is committed to advancing its rare disease pr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zealand-pharma-zldpf-q4-2024-070456939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ZLDPF","NVO"],"gpt_icon":1},{"id":"2512449207","title":"Zealand Pharma convenes its Annual General Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2512449207","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512449207?lang=en_us&edition=fundamental","pubTime":"2025-02-20 20:00","pubTimestamp":1740052800,"startTime":"0","endTime":"0","summary":"Notice to convene the Annual General Meeting 2025 of Zealand Pharma A/S  .The Board of Directors of the Company hereby convenes the Annual General Meeting of the Company to be held on:. The Annual General Meeting will be held as a partly electronic general meeting with the possibility of attending electronically or in person .The Annual General Meeting will be held electronically via the virtual portal hosted by Computershare A/S, and physically at the Company's registered address Sydmarken 11, DK-2860 Sborg.Please find further information in the accompanying attachment.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zealand-pharma-convenes-annual-general-120000102.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CET","ZLDPF"],"gpt_icon":0},{"id":"2512495857","title":"Zealand Pharma Announces Financial Results for the Full Year 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2512495857","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512495857?lang=en_us&edition=fundamental","pubTime":"2025-02-20 14:00","pubTimestamp":1740031200,"startTime":"0","endTime":"0","summary":"A transformational year with significant clinical advancement across differentiated obesity pipeline, while building the foundation for accelerated growth in the years to come. Positive results with long-acting amylin analog petrelintide in 16-week Phase 1b trial and advancement into large, comprehensive Phase 2b trial in people with overweight or obesity. Positive topline results with GLP-1/GLP-2 receptor dual agonist dapiglutide in 13-week Phase 1b trial and expansion of trial to investigate higher doses over a longer treatment period. The strong cash position enables Zealand Pharma to significantly accelerate its investments in the company’s wholly-owned obesity programs, which in 2025 will include three large Phase 2b trials. Net operating expenses expected in 2025 are mostly driven by research and development. Development costs primarily relate to the clinical advancement of the wholly-owned obesity programs, including Phase 2b trials, CMC activities related to API and Drug Produc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zealand-pharma-announces-financial-results-060000430.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0390134368.USD","BK4139","BK4121","BK4530","BK4588","CRL","ZLDPF","SBS","BK4585","CHI","BK4172"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":36,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ZLDPF\",params:#limit:5,,,undefined,":[{"date":"2024-05-16","symbol":"ZLDPF","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1715846400000,"name":null,"time":"Pre-Market","dateTimestamp":1715832000000,"actualEps":null},{"market":"US","date":"2022-11-10","symbol":"ZLDPF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1668056400000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ZLDPF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ZLDPF\",market:\"US\",delay:false,,,undefined,":{}}}